title: Effect of beta-glucans on the nitric oxide synthesis by peritoneal macrophage in mice.
abstract: Nitric oxide (NO) is an important effector molecule on antimicrobial and antitumor effects of macrophages. (1 -> 3)-beta-D-Glucan (beta-glucan) is well known to show various immunopharmacological effects such as antimicrobial effect and antitumor effect by activating various points of host defense mechanisms. This paper deals with NO synthetic activity of peritoneal macrophage (PM) induced by beta-glucan administration in mice. The activity was determined by measuring NO concentration in PM culture by Griess reagent after 24 or 48 h in vitro culture. Administration (i.p. or i.v.) of a branched soluble (1 -> 3)-beta-D-glucan, grifolan (GRN), from Grifola frondosa enhanced NO synthesis of PM dose and time dependently. The activity was abrogated by the addition of N(G)-monomethyl-L-arginine (L-NMMA) in vitro. The most significant activity was observed at 3-7 d after the administration of GRN (250 mu g/mouse). PM from all strains of ICR, C3H/HeN, C3H/HeJ, BALB/c, BALB/c nu/nu, C57BL, and AKR mice showed significant activity by GRN administration. Among beta-glucans tested, SSG and OL-2, highly branched soluble glucans, and a particulate beta-glucan, zymosan, showed similar activity. Addition of GRN directly to in vitro RAW 264.7 or proteose peptone induced peritoneal macrophage (PP-PEC) culture could not enhance NO synthesis. However, NO synthesis of PP-PEC was enhanced in vitro by addition of GRN in the presence of interferon gamma (IFN gamma). Gene expression of IFN gamma mRNA in the liver and PEC were enhanced in GRN administered mice assessed by reverse transcriptase assisted PCR (RT-PCR) method. These facts strongly suggested that beta-glucan has capacity to enhance NO synthesis of PM in vivo through IFN gamma mediated mechanism.
authors.affiliation: School of Pharmacy, Tokyo University Pharmacy and Life Science, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Ohno
authors.forename: Y
authors.initials: Y
authors.lastname: Egawa
authors.forename: T
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
authors.forename: T
authors.initials: T
authors.lastname: Yadomae
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015870:Gene Expression; D005936:Glucans / Q000494:pharmacology; D007371:Interferon-gamma / Q000096:biosynthesis / Q000502:physiology; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D016133:Polymerase Chain Reaction; D015054:Zymosan / Q000494:pharmacology; D047071:beta-Glucans; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D000276:Adjuvants, Immunologic; D004791:Enzyme Inhibitors; D005936:Glucans; D047071:beta-Glucans; C048444:grifolan; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D007371:Interferon-gamma; D015054:Zymosan; C033363:beta-1,3-glucan; C074376:OL 2; D019001:Nitric Oxide Synthase